Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Sty ...

Key Takeaways PLSE partners to start a clinical study using the nPulse technology for papillary thyroid microcarcinoma.The FDA grants the IDE application for an early trial, enrolling 30 patients in 2026.The alliance expands the PLSE's clinical breakthrough in non-thermal soft-tissue ablation.Pulse Biosciences, Inc. (PLSE)  announced that it initiated a research collaboration with The University of Texas MD Anderson Cancer Center to test its nPulse technology — Vybrance — for treating malignant thyroid tumo ...

Core Viewpoint - Yunqi Capital Limited, holding a 5.1% stake in STAAR Surgical Company, has expressed strong opposition to Alcon Inc.'s revised acquisition offer of $30.75 per share, emphasizing that the sale process has been mishandled and does not maximize shareholder value [2][5][4]. Group 1: Acquisition Details - Alcon agreed to acquire STAAR Surgical for a total equity value of approximately $1.5 billion, which was later amended to $30.75 per share, raising the total equity value to approximately $1.6 billion [3]. - The revised purchase price represents an additional approximately $150 million in equity value for STAAR's stock [3]. Group 2: Shareholder Concerns - Broadwood Partners, owning a 30.2% stake in STAAR, criticized the sale process, stating that the new price is still roughly half of what Alcon offered in 2024, despite STAAR's projections remaining unchanged [4]. - Yunqi Capital believes it is not the right time to sell the company and argues that the sale process has been structured to favor Alcon, lacking transparency and failing to attract competitive bidders [5][6]. Group 3: Process Issues - The 30-day go-shop period was deemed too short for a credible market check for a global medical device company, with provisions that discouraged alternative buyers [6]. - STAAR reportedly contacted 21 parties, but Yunqi Capital claims the pool of potential buyers is significantly larger, indicating that the process may have deterred additional bidders [7]. Group 4: Market Performance - STAAR Surgical shares were down 5.65% at $23.95 at the time of publication, reflecting market concerns regarding the acquisition and the company's future prospects [8].

Ottawa, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The global MRI 3T cochlear implant market size is calculated at USD 902.78 million in 2025 and is expected to reach around USD 2101.54 million by 2034, growing at a CAGR of 9.96% for the forecasted period. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6392 Key Takeaways North America dominated the market in 2024, with a revenue share of 40%.Asia Pacific is expe ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zack ...

SAN DIEGO--(BUSINESS WIRE)-- #Medtech--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced it has received FDA 510(k) clearance for its next-generation vMap® technology. The clearance expands vMap's non-invasive mapping capabilities with several major enhancements, including atrial flutter mapping, direct ECG and data streaming with electroanatomic mapping systems, 3D model import and visualization, conversion of vMap into a Software as a Medical Device (SaMD. ...

Core Points - Modular Medical, Inc. has announced a public offering of 12,173,000 shares of common stock along with warrants to purchase an additional 6,086,500 shares [1] - The offering price is set at $0.77 for two shares of common stock and one accompanying warrant, resulting in an effective price of $0.38 per share and $0.01 per warrant [1] Company Overview - Modular Medical specializes in insulin delivery technology and has developed the first FDA-cleared patch pump aimed at adult "almost-pumpers" [1] - The company's product is designed to be user-friendly and affordable, targeting a specific segment of the diabetes management market [1]

Core Insights - Pzena Investment Management's third-quarter 2025 commentary indicates a strong performance in US broad-based indexes driven by optimism about AI and a rate cut in September, with the technology sector leading growth [1] - The Pzena Focused Value strategy returned 1.1% gross and 0.9% net, underperforming the Russell 1000 Value Index, which returned 5.3% [1] Company Overview: Solventum Corporation - Solventum Corporation (NYSE:SOLV) is a healthcare company with segments in Medsurg, Dental Solutions, and Health Information Systems [2] - The stock of Solventum Corporation had a one-month return of 8.51% and a 52-week gain of 13.65%, closing at $80.11 per share with a market capitalization of $13.895 billion on December 09, 2025 [2] Investment Positioning - Pzena Focused Value Strategy initiated a new position in Solventum Corporation, citing operational challenges and margin pressure from its spinoff from 3M as an attractive entry point [3] - The company is expected to benefit from self-help opportunities as an independent entity and has a clean balance sheet following the divestment of a non-core asset at a premium valuation [3] Hedge Fund Interest - Solventum Corporation was held in 42 hedge fund portfolios at the end of the third quarter, an increase from 37 in the previous quarter [4] - Despite the potential of Solventum Corporation, the company is viewed as having less upside compared to certain AI stocks, which are considered to carry less downside risk [4]

Core Viewpoint - IceCure Medical's ProSense® cryoablation technology is gaining recognition and acceptance in the medical community for treating breast cancer, as evidenced by the presentation of four independent studies at the RSNA Annual Meeting 2025 [1][2][3] Group 1: Study Presentations - Four abstracts featuring independent studies on ProSense® were accepted at the RSNA Annual Meeting, highlighting the technology's effectiveness and growing adoption [2][3] - The studies involved a total of 263 patients, showcasing diverse patient populations and supporting broader adoption of the ProSense® system [1][2] Group 2: Key Findings from Studies - **Study 1**: Ultrasound-guided Cryoablation for Breast Cancer in Non-Surgical Patients - 100% success rate in treating luminal cancers up to 2.5 cm, with complete tumoral necrosis achieved in 81.2% of cases [4][5] - **Study 2**: Non-Surgical Treatment of Breast Cancer - Cryoablation combined with hormonal therapy resulted in an 83.3% tumor size reduction, significantly outperforming hormonal therapy alone [6][7] - **Study 3**: Correlation of Lesion Conspicuity in CEM with Biopsy Results - A significant association was found between lesion conspicuity on CEM and biopsy results, indicating that lower conspicuity correlates with higher cryoablation success [8][9] Group 3: ProSense® System Overview - ProSense® is the first FDA-approved device for local treatment of low-risk breast cancer in women aged 70 and above, providing a non-surgical option for patients unsuitable for surgery [9][10] - The system utilizes liquid nitrogen to create large lethal zones for effective tumor destruction, enhancing patient recovery and reducing surgical risks [10][12] Group 4: Company Background - IceCure Medical focuses on developing advanced cryoablation therapy systems for various cancers, with a commitment to providing safe and effective alternatives to surgical tumor removal [13]

Core Insights - STERIS plc is a leading provider of infection prevention products and services, with a market capitalization of $25.7 billion, offering a diverse range of medical equipment and consumables [1][2] Company Overview - STERIS is categorized as a large-cap stock, emphasizing its significant size and influence in the medical devices industry, particularly in infection prevention [2] - The company’s diverse portfolio serves as a comprehensive solution for healthcare providers, enhancing revenue and customer retention [2] Stock Performance - STERIS shares have experienced a decline of 4.2% from their 52-week high of $268.60, reached on November 25 [3] - Over the past three months, the stock has gained 3.6%, underperforming the S&P 500 Index, which saw a 5% increase [3] - In the longer term, STERIS shares rose 6% over six months, lagging behind the S&P 500's 13.9% gains, but have outperformed the index with a 19.3% increase over the past 52 weeks compared to the S&P 500's 13% [4] Recent Financial Results - On November 5, STERIS reported Q2 results, with revenue of $1.5 billion, exceeding analyst expectations of $1.4 billion [5] - The adjusted EPS of $2.47 also surpassed analyst estimates by 5.1% [5] - In contrast, Stryker Corporation, a competitor, has seen its stock decline by 8.4% over the past 52 weeks [5] Analyst Sentiment - Wall Street analysts maintain a bullish outlook on STERIS, with a consensus "Moderate Buy" rating from nine analysts [6] - The mean price target for STERIS is $288.86, indicating a potential upside of 12.3% from current price levels [6]